ESMO 2026: Early CAR-T and Bispecific Data in Liver Cancer, LEAP-012 Falls Short
Start here
At ESMO 2026, three studies in advanced hepatocellular carcinoma delivered mixed results. Phase I updates for C-CAR031 and BGB-B2033 showed preliminary antitumor activity: C-CAR031 achieved an objective response rate of 44% and disease control rate of 92% in 36 patients, though tumor lysis syndrome-related deaths and interstitial lung disease were reported. BGB-B2033 showed confirmed objective response rates ranging from 16.0% to 35.7% across dose groups in 110 patients, with 450 mg selected as the recommended phase II dose. In contrast, the long-term analysis of LEAP-012 showed no overall survival benefit. Both early-phase programs now move forward with larger trials to confirm safety and efficacy.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comESMO 2026 HCC Updates: C-CAR031 and BGB-B2033 Show Preliminary Efficacy, LEAP-012 Long-Term Analysis Shows No OS Benefit
ESMO 2026 published abstracts from three advanced HCC studies. Phase I updates for C-CAR031 and BGB-B2033 showed preliminary antitumor activity, while the long-term LEAP-012 analysis showed no OS benefit. C-CAR031 achieved an ORR of 44% and DCR of 92% in 36 patients, with tumor lysis syndrome-related deaths and interstitial lung disease reported; confirmed ORR across BGB-B2033 dose groups in 110 patients ranged from 16.0% to 35.7%, and 450 mg was selected as the recommended phase II dose.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 23 21:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.